journal article·2025-09-24

Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events

Cai Yang, Lizhuan Zhang, Yuying Yang, Minhui Su, Mengyuan Jiang, Juncai Li, Dailiang Zhang, Yang Sun, Ding Ding, Haoran Jia, Sitao Xie, Xiangsheng Liu, Ting Fu, Cheng Cui, Zhen Du, Weihong Tan

Nano Letters· Volume 25· Issue 38
Publisher page

Abstract

Interleukin-12 (IL-12) is a robust proinflammatory cytokine that activates immune cells, such as T cells and natural killer cells, to induce antitumor immunity. However, the clinical application of recombinant IL-12 has been limited by systemic immune-related adverse events (irAEs) and rapid degradation. To address these challenges, we employed mRNA technology to encode a tumor-activated IL-12 "lock" fusion protein that offers both therapeutic efficacy and systemic safety. Lock-IL-12 mRNA encodes a sequence consisting of the IL-12 receptor-binding domain, a matrix metalloproteinase-2 (MMP-2)-cleavable linker, and two IL-12 subunits. Systemic delivery of the mRNA via lipid nanoparticles (LNPs) enables widespread systemically expression of Lock-IL-12 protein in the locked state, and maintaining an inactive state during circulation. Upon reaching the MMP-2-rich tumor microenvironment (TME), the fusion protein undergoes cleavage, activating IL-12 to initiate a powerful antitumor immune response. This strategy represents a promising approach for cytokine-based tumor therapy, combining efficient delivery with minimal systemic toxicity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: CAR-T cell therapy research · Virus-based gene therapy research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province

Hunan University

The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Zhejiang Cancer Hospital

Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences

Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering

Shanghai Jiao Tong University

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (41)

Show source-provided references
1. 10.1016/0167-5699(93)90173-I10.1016/0167-5699(93)90173-I ↗
2. 10.1084/jem.177.4.119910.1084/jem.177.4.1199 ↗
3. 10.1002/eji.183026073610.1002/eji.1830260736 ↗
4. 10.1084/jem.173.4.86910.1084/jem.173.4.869 ↗
5. 10.1038/nri100110.1038/nri1001 ↗
6. 10.1158/0008-5472.CAN-09-114510.1158/0008-5472.CAN-09-1145 ↗
7. 10.1038/cdd.2014.13410.1038/cdd.2014.134 ↗
8. 10.1038/s41467-020-20599-x10.1038/s41467-020-20599-x ↗
9. 10.1038/s41467-024-49582-610.1038/s41467-024-49582-6 ↗
10. 10.1038/s41467-023-40115-110.1038/s41467-023-40115-1 ↗
11. 10.1038/s41565-023-01580-310.1038/s41565-023-01580-3 ↗
12. 10.1016/j.jconrel.2023.02.02910.1016/j.jconrel.2023.02.029 ↗
13. 10.1126/sciimmunol.abi689910.1126/sciimmunol.abi6899 ↗
14. 10.1200/JCO.2003.12.11910.1200/JCO.2003.12.119 ↗
15. 10.1002/advs.20220513910.1002/advs.202205139 ↗
16. 10.1016/j.biomaterials.2010.09.05810.1016/j.biomaterials.2010.09.058 ↗
17. 10.1038/s41551-020-0549-210.1038/s41551-020-0549-2 ↗
18. 10.1038/labinvest.2015.12610.1038/labinvest.2015.126 ↗
19. 10.1002/ijc.2375610.1002/ijc.23756 ↗
20. 10.1038/s41416-018-0328-y10.1038/s41416-018-0328-y ↗
21. Atkins M. B. · Clin. Cancer Res. · 1997 · 3 · 409
22. 10.1016/j.leukres.2009.01.02010.1016/j.leukres.2009.01.020 ↗
23. Leonard J. P. · Blood · 1997 · 90 · 2541
24. 10.1158/1078-0432.CCR-03-030410.1158/1078-0432.CCR-03-0304 ↗
25. 10.1158/1078-0432.CCR-11-048210.1158/1078-0432.CCR-11-0482 ↗
26. 10.1016/S0140-6736(23)02444-310.1016/S0140-6736(23)02444-3 ↗
27. 10.1177/205101361350872910.1177/2051013613508729 ↗
28. 10.1038/s41568-023-00586-210.1038/s41568-023-00586-2 ↗
29. 10.1021/jacs.3c1400510.1021/jacs.3c14005 ↗
30. 10.1021/jacs.3c1401010.1021/jacs.3c14010 ↗
31. 10.1038/nrd427810.1038/nrd4278 ↗
32. 10.1016/j.ccell.2019.10.00610.1016/j.ccell.2019.10.006 ↗
33. 10.1158/1078-0432.CCR-20-047210.1158/1078-0432.CCR-20-0472 ↗
34. 10.1038/s43018-020-0095-610.1038/s43018-020-0095-6 ↗
35. 10.1016/j.jconrel.2022.03.02110.1016/j.jconrel.2022.03.021 ↗
36. 10.1158/1078-0432.CCR-19-364210.1158/1078-0432.CCR-19-3642 ↗
37. 10.1038/s41551-022-00888-010.1038/s41551-022-00888-0 ↗
38. 10.1084/jem.2022074510.1084/jem.20220745 ↗
39. 10.1089/jir.2018.012910.1089/jir.2018.0129 ↗
40. 10.1038/s41467-022-28279-810.1038/s41467-022-28279-8 ↗
41. 10.1073/pnas.93.24.1400210.1073/pnas.93.24.14002 ↗